Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Chronic spontaneous urticaria
Economic burden and healthcare resource utilization
9 evidence topics · 9 sources
Annual healthcare costs and resource use in a commercially insured US population, research paid by Genentech
“The prevalence of chronic idiopathic or spontaneous urticaria is 0.11 % in a commercially insured US population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Oral corticosteroids were the most commonly prescribed medication, used in 54.7 % of patients. Patients accumulated a mean of 15.1 office visits per year (standard deviation 12.6). The mean all-cause healthcare cost totaled over US$9000 per year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean all-cause healthcare costs were US$9142 (SD US$21,835, median US$3659) (Fig. 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean urticaria-related costs were US$997 (SD US$2322, median US$612).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“M.S. Broder and E. Chang are employed by Partnership for Health Analytic Research, LLC, a health services research company paid by Genentech, Inc. to conduct this research.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Uncontrolled CSU, resource use, and costs in US HealthVerity claims
“Adults with a record of CSU diagnosis within the US HealthVerity claims database were eligible.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 200,298 patients were followed-up for a median of 2.3 years after diagnosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Corticosteroids were the most prescribed treatment during follow-up among the 166,195 patients prescribed at least 1 treatment (94.3%). Proxy events were observed in 59.1% of the patients. HCRU and health care costs increased from baseline in patients with uncontrolled CSU during follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of patients with CSU who were prescribed treatment, more than 50% experienced uncontrolled CSU, which was associated with increased HCRU and health care costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Systemic corticosteroid use, adverse events, and resource use in US HealthVerity claims, Novartis-funded
“This retrospective cohort study used data from the US HealthVerity claims database of adults with diagnosed CSU (January 2016–March 2023).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 200,298 patients, corticosteroids were the most prescribed treatment (78.3% all; 68.2% systemic) following CSU diagnosis, excluding over-the-counter medication and antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More frequent HCRU was generally observed after the first systemic corticosteroid prescription and with increasing duration of corticosteroid use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More frequent HCRU may also have additional implications for health care costs, which are not discussed here.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study and article publication, including the journal’s Rapid Service Fee, was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual direct and indirect costs in 50 adults at allergy and dermatology clinics
“The Johns Hopkins University allergy and dermatology ambulatory clinics.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fifty adults with active CIU were recruited in sequential order.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with CIU consumed a mean (SD) of $2047 ($1483) annually. Because CIU is primarily an outpatient disease, medication costs alone accounted for 62.5% ($1280) of the total annual cost. Indirect costs accounted for 15.7% ($322) of the total costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
ASSURE-CSU: direct, indirect, and out-of-pocket costs by country and resource use
“Total average (SD) annual direct costs per patient per year, as captured in the retrospective medical record review, ranged from PPP$907.1 ($2431.14) in Italy to PPP$2984.2 ($8969.46) in France. The major drivers of these costs were therapies (range, PPP$426.4‐$1788.7) and inpatient visits (range, PPP$250.7‐$1074.4) (Tables S5 and S6 in Appendix S5 and S6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Average indirect costs, or costs of patient‐reported total work productivity loss over 4 weeks, were driven primarily by the cost of presenteeism (range, PPP$544.5‐$1180.0); the mean (SD) cost of work productivity loss ranged from PPP$544.8 ($603.22) in France to PPP$1287.4 ($1123.80) in Germany (Table S7 in Appendix S7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, in ASSURE‐CSU, CSU‐related out‐of‐pocket expenses to patients averaged nearly PPP$500 per year and approached PPP$1000 in Canada.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 97 patients (14.4%) with at least one CSU‐related ED visit in the past 12 months, the annual mean (SD) number of visits was 1.8 (1.26). Hospitalization for CSU was recorded for 55 patients (8.2%), with a mean (SD) length of stay per hospitalization of 3.7 (2.67) days” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Self-reported all-cause resource use over 6 months, 2019 National Health and Wellness Survey
“Data from respondents with physician-diagnosed CSU were collected from the 2019 National Health and Wellness Survey (NHWS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In terms of all-cause HCRU, 96.5% of the respondents had visited any healthcare provider in the past 6 months, and 60.2% reported visiting an emergency department a mean (SD) of 8.6 (11.9) and 3.7 (5.0) times, respectively. Meanwhile, 55.9% of respondents had been hospitalized in the past 6 months, with the mean (SD) number of hospitalizations being 4.4 (9.8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Review of the global burden of chronic urticaria: treatment and total cost ranges
“Here we review the impact of CU on different aspects of patients' quality of life and the burden of this chronic disease for the patient and society.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Apart from treatment costs, with annual values between 900 and 2400 purchasing power parity dollars (PPP$) in Europe and the USA, CU is associated with a high consumption of medical resources and other indirect costs, which may reach a total annual cost of PPP$ 15 550.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Omalizumab spending in Oregon all-payer claims, all indications, 2024
Cost of routine laboratory screening in adults with CSU: US simulation
“Average laboratory costs per simulated patient with CSU were $573 (standard deviation [SD], $41), with only 0.16% (SD, 3.99%) of tests resulting in improved clinical outcomes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“From a simulated US population perspective, nation-wide screening costs could reach $941,750,741 to $1,833,501,483.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote